A randomized, double-blind, placebo-controlled that will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CIN-109 delivered subcutaneously (SC) in obese, otherwise healthy subjects
Latest Information Update: 29 Dec 2023
At a glance
- Drugs CIN 109 (Primary)
- Indications Obesity
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 14 Dec 2023 Status changed from recruiting to completed, according to a CinRx Pharma media release.
- 14 Dec 2023 According to a CinRx Pharma media release, this study has recently completed its multiple ascending dose (MAD) study.
- 29 Sep 2021 New trial record